N, % | p-value | |||
---|---|---|---|---|
ER positive | UCC | 6 | 13% | |
UEnd | 18 | 64% | 1.2 E−05 | |
OvCC | 0 | 0% | 0.65 | |
PR positive | UCC | 4 | 8% | |
UEnd | 15 | 54% | 4.8 E−05 | |
OvCC | 0 | 0% | 0.90 | |
P16 positive | UCC | 18 | 38% | |
UEnd | 14 | 50% | 0.41 | |
OvCC | 4 | 50% | 0.78 | |
P53 mutant profile | UCC | 11 | 23% | |
UEnd | 6 | 21% | 0.94 | |
OvCC | 1 | 13% | 0.75 | |
PTEN loss | UCC | 28 | 58% | |
UEnd | 18 | 64% | 0.79 | |
OvCC | 4 | 50% | 0.96 | |
PDL1 positive | UCC | 4 | 8% | |
UEnd | 0 | 0% | 0.30 | |
OvCC | 0 | 0% | 0.92 | |
MMRd | UCC | 19 | 40% | |
UEnd | 9 | 32% | 0.69 | |
OvCC | 0 | 0% | 0.07 | |
MMRd2 | UCC | 10 | 21% | |
UEnd | 6 | 21% | 1 | |
OvCC | 0 | 0% | 0.36 | |
Mean (SD) | ||||
EZH2 expressiona | UCC | 24.3% (39.2) | 0.38, Kruskal–Wallis | |
UEnd | 36.6% (41.7) | |||
OvCC | 17.5% (26.0) | |||
γH2AX expressiona | UCC | 18.3% (31.1) | 0.54, Kruskal–Wallis | |
UEnd | 24.7% (38.1) | |||
OvCC | 11.4% (29.8) |